Appearing as a promising advance in the battle against obesity, the drug is generating considerable attention . This treatment combines properties of two established GLP-1 receptor agonists, liraglutide, with an unique glucose-dependent incretin component. Preliminary patient results have shown impressive weight loss in people with a high BMI ,… Read More